Genopathy
Gene-Disorder Association · Article
Gene
TP53
Tumor Protein P53
Approved treatment annotated
Association Review

In brief

The association between TP53 (Tumor Protein P53) and Rhabdomyosarcoma is supported by expert-curated evidence, drawing on a single expert-curated source, which records pathogenic variants.

Sources 1
Clinical variants 12
Symptoms 0
Compounds 2
Trials 26of 1,672 via TP53 compounds
Publications 0
01
At a glance

Association overview

A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.

Request access
02
Provenance

Evidence and sources

1 source

Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.

Request access
03
TP53

The gene

3 source summaries

A gene summary alongside the source descriptions it was distilled from.

Request access
04
Rhabdomyosarcoma

The disorder

13 database identifiers

The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).

Request access
05
ClinVar and variant evidence

Genetic basis

12 clinical variants

ClinVar variants reported for this pair, with disorder-specific significance, review status, molecular consequence and origin.

Request access
06
Interventions

Therapeutics

2 compounds & drugs

Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.

Request access
07
Human studies

Clinical trials

1,672 clinical trials

Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.

Request access
08
Provenance

References & sources

6 references

Every source and publication cited across this dossier, as one numbered reference list.

Request access